
GlaxoSmithKline plc GSK
$ 50.38
-1.02%
Annual report 2025
added 04-18-2026
GlaxoSmithKline plc Gross Profit 2011-2026 | GSK
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit GlaxoSmithKline plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.6 B | 22.3 B | 21.8 B | 19.8 B | 16.5 B | 16.4 B | 21.9 B | 20.6 B | 19.8 B | 18.6 B | 15.1 B | 15.7 B | 17.9 B | 18.5 B | 20.1 B |
All numbers in GBP currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23.6 B | 15.1 B | 19.2 B |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | ||
|
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
5.51 M | - | 2.54 % | $ 160 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | ||
|
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - | ||
|
ACADIA Pharmaceuticals
ACAD
|
473 M | $ 22.35 | 0.72 % | $ 3.7 B | ||
|
Galapagos NV
GLPG
|
896 M | $ 28.39 | -0.13 % | $ 2.69 B | ||
|
Grifols, S.A.
GRFS
|
2.79 B | $ 8.27 | 0.49 % | $ 6.83 B | ||
|
Advaxis
ADXS
|
90 K | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.03 M | $ 3.5 | 5.42 % | $ 5.76 M | ||
|
Aeterna Zentaris
AEZS
|
2.65 M | - | 5.93 % | $ 314 M | ||
|
CureVac N.V.
CVAC
|
-10.6 M | - | - | $ 867 M | ||
|
AIkido Pharma
AIKI
|
10 K | - | 1.93 % | $ 17.4 M | ||
|
InflaRx N.V.
IFRX
|
-7.24 M | $ 1.97 | -7.51 % | $ 152 M | ||
|
Aptinyx
APTX
|
1.56 K | - | -39.0 % | $ 4.57 M | ||
|
Albireo Pharma
ALBO
|
39.2 M | - | -0.23 % | $ 916 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-523 K | - | -11.43 % | $ 502 K | ||
|
Aravive
ARAV
|
5.68 K | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
1 K | - | 17.91 % | $ 11.1 M | ||
|
Innate Pharma S.A.
IPHA
|
23.8 M | $ 1.4 | -2.1 % | $ 235 M | ||
|
Ayala Pharmaceuticals
AYLA
|
90 K | - | - | $ 7.46 M | ||
|
Завод ДИОД
DIOD
|
325 M | - | - | - | ||
|
Фармсинтез
LIFE
|
160 M | - | - | - | ||
|
AstraZeneca PLC
AZN
|
48.1 B | - | - | $ 96.9 B |